Genentech, Ionis Reveal Positive Interim Data From Phase III Sefaxersen Study In IgA Nephropathy

Genentech, an affiliate of Roche, and Ionis Pharmaceuticals reported positive prespecified interim results from the ongoing Phase III IMAgINATION study of investigational sefaxersen. The favorable late-stage clinical update supports the drug's development outlook and could be a positive catalyst for Roche and Ionis, although the article excerpt provides no efficacy, safety, or financial details.